文献速递核素与放射性配体治疗肿瘤 PET/CT

124I-MIBG PET/CT 在嗜铬细胞瘤中的诊断效能

Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma.
PubMed 文献 · J Nucl Med · 2021-09-23

该研究纳入43例疑似(复发)嗜铬细胞瘤患者,以病理或临床验证为标准,评估124I-MIBG PET/CT的诊断效能,并比较13例已知恶性嗜铬细胞瘤患者中该技术与增强CT的检出率。结果显示124I-MIBG PET/CT敏感度86%、特异度100%,在恶性患者中阳性率85%,联合增强CT可检出173个病灶。

要点

  • 124I-MIBG PET/CT诊断嗜铬细胞瘤敏感度86%、特异度100%。
  • 在13例恶性嗜铬细胞瘤患者中,124I-MIBG PET阳性率为85%。
  • 联合增强CT检出173个病灶,124I-MIBG PET可见166个(96%),增强CT可见118个(68%)。

核心结论

  • 124I-MIBG PET/CT在初诊分期中诊断嗜铬细胞瘤准确性高,在再分期中检出率高。

研究设计与样本

  • 研究分析43例连续疑似(复发)嗜铬细胞瘤患者,以组织病理学(n=25)和临床验证(n=18)为标准真值。
  • 另在13例已知转移性恶性嗜铬细胞瘤患者中,按患者和病灶比较124I-MIBG PET与增强CT的检出率。

主要发现

  • 43例疑似患者中,124I-MIBG PET/CT阳性19例(44%),最终确认嗜铬细胞瘤22例(51%)。
  • 124I-MIBG PET/CT的敏感度、特异度、阳性预测值和阴性预测值分别为86%、100%、100%和88%。
  • 13例恶性嗜铬细胞瘤患者中,124I-MIBG PET阳性11例(85%)。
  • 联合124I-MIBG PET与增强CT共检出173个病灶,其中124I-MIBG PET可见166个(96%),增强CT可见118个(68%)。

关键数值与推荐

  • 124I-MIBG PET/CT诊断嗜铬细胞瘤的敏感度86%、特异度100%、阳性预测值100%、阴性预测值88%。
  • 恶性嗜铬细胞瘤患者中124I-MIBG PET阳性率85%(11/13)。
  • 联合检查检出173个病灶,124I-MIBG PET检出率96%(166/173),增强CT检出率68%(118/173)。

临床怎么用

  • 124I-MIBG PET/CT可用于疑似嗜铬细胞瘤的初始分期和再分期,具有高特异度。
  • 在已知恶性嗜铬细胞瘤患者中,124I-MIBG PET对病灶检出率高于增强CT。
  • 未来需评估124I-MIBG PET对治疗指导(包括个体化131I-MIBG治疗)的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

123/131I-metaiodobenzylguanidine (MIBG) scintigraphy has shown a high specificity for imaging pheochromocytoma and paraganglioma, but with low sensitivity because of low spatial resolution. 124I-MIBG PET may be able to overcome this limitation and improve the staging of patients with (suspected) pheochromocytoma. Methods: We analyzed the sensitivity, specificity, and positive and negative predictive values of 124I-MIBG PET in 43 consecutive patients with suspected (recurrence of) pheochromocytoma using histopathologic (n = 25) and clinical validation (n = 18) as the standard of truth. Furthermore, we compared the detection rate of 124I-MIBG PET versus contrast-enhanced (CE) CT on a per-patient and per-lesion basis in 13 additional patients with known metastatic malignant pheochromocytoma. Results:124I-MIBG PET/CT was positive in 19 (44%) of 43 patients with suspected pheochromocytoma. The presence of pheochromocytoma was confirmed in 22 (51%) of 43. 124I-MIBG PET/CT sensitivity, specificity, and positive and negative predictive values were 86%, 100%, 100%, and 88%, respectively. 124I-MIBG PET was positive in 11 (85%) of 13 patients with malignant pheochromocytoma. Combined 124I-MIBG PET and CE CT detected 173 lesions, of which 166 (96%) and 118 (68%) were visible on 124I-MIBG PET and CE CT, respectively. Conclusion:124I-MIBG PET detects pheochromocytoma with high accuracy at initial staging and a high detection rate at restaging. Future assessment of 124I-MIBG PET for treatment guidance, including personalized 131I-MIBG therapy, is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Weber M, Schmitz J, Maric I, et al. Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma. J Nucl Med. 2021. PMID: 34556526. doi:10.2967/jnumed.121.262797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。